Tang Yao, Liu Bo, Ma Aijia, Wang Bo, Xiong Huaiyu, Zhou Yi, Yang Jing, Kang Yan
Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
West China Hospital, Institutes for Systems Genetics, Sichuan University, Chengdu, China.
Front Microbiol. 2025 May 30;16:1586949. doi: 10.3389/fmicb.2025.1586949. eCollection 2025.
The lung microbiota, present in healthy individuals, undergoes alterations in different diseases and is closely linked to changes in both systemic and alveolar immunity. These interactions play a crucial role in the onset and progression of numerous diseases. Acute respiratory distress syndrome (ARDS), one of the most severe conditions encountered in intensive care units (ICU), is characterized by high incidence and mortality rates. The pathophysiology of ARDS involves complex mechanisms, including the activation and dysregulation of overlapping pathways related to injury, inflammation, and coagulation, both locally in the lungs and systemically. Notably, alterations in the microbiota may contribute to the pathogenesis of ARDS. Emerging evidence suggests that changes in the lung microbiota are associated with ARDS development, often marked by increased bacterial burden, reduced microbial diversity, and shifts in microbiota composition. In this review, we focus on the regulatory roles of the lung microbiota in ARDS and their therapeutic potential.
健康个体体内存在的肺部微生物群在不同疾病中会发生改变，并且与全身免疫和肺泡免疫的变化密切相关。这些相互作用在众多疾病的发生和发展中起着至关重要的作用。急性呼吸窘迫综合征（ARDS）是重症监护病房（ICU）中最严重的病症之一，其特点是发病率和死亡率高。ARDS的病理生理学涉及复杂的机制，包括在肺部局部和全身与损伤、炎症和凝血相关的重叠途径的激活和失调。值得注意的是，微生物群的改变可能有助于ARDS的发病机制。新出现的证据表明，肺部微生物群的变化与ARDS的发展有关，通常表现为细菌负荷增加、微生物多样性降低和微生物群组成的改变。在这篇综述中，我们重点关注肺部微生物群在ARDS中的调节作用及其治疗潜力。
